Tech Company Financing Transactions

HepaRegeniX Funding Round

HepaRegeniX secured a $16 million Series C funding round on 7/10/2024. Investors included Vesalius Biocapital, Boehringer Ingelheim Venture Fund and High-Tech Gründerfonds.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Life Sciences

Mailing Address

Eisenbahnstraße 63
Tübingen, 72072
Germany

Phone

+49 (0)7071 7912810

Website

www.heparegenix.com

Email Address

[email protected]

Overview

HepaRegeniX GmbH is a clinical stage company developing novel therapies for the treatment of acute and chronic liver diseases. Since its start in 2017, HepaRegeniX has successfully discovered and developed several drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular target Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Operating Officer

Wolfgang Albrecht

        

Chief Scientific Officer

Birgit Jung

        

Browse more venture capital transactions:

Prev: 7/10/2024: ThirdFi venture capital transaction
Next: 7/10/2024: Granta Autonomy venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to record every notable VC transaction. All VC database entries on this site are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary